![Thomas R. Parr](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Thomas R. Parr
No open positions remaining
Profile
Thomas R.
Parr worked as President & Acting Chief Executive Officer at MicroGenomics, Inc. and as Senior Director-Microbiology at IntraBiotics Pharmaceuticals, Inc. and Xenogen Corp.
He was also the Chief Scientific Officer & Head-Montreal Site at Targanta Therapeutics Corp.
and Chief Scientific Officer at Targanta Therapeutics, Inc. Additionally, he worked as Vice President-Research at Adaptive Therapeutics, Inc. and as Principal at Lilly Research Laboratories.
He is currently the Chief Scientific Officer at Spero Therapeutics, Inc. Prior to his career in industry, he was an Assistant Professor at the University of Ottawa.
He received his undergraduate degree from the University of Minnesota and his graduate and doctorate degrees from the University of Calgary.
Former positions of Thomas R. Parr
| Companies | Position | End |
|---|---|---|
| SPERO THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 30/06/2022 |
Fedora Pharmaceuticals, Inc.
 Fedora Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Fedora Pharmaceuticals, Inc. is an American private biopharmaceutical company focused on discovering and developing novel antimicrobial agents to address antimicrobial resistance. The company is located in the US. The company targets multi-drug resistant pathogens, including WHO-identified ESKAPE pathogens, and its lead product, nacubactam, is a phase 3-ready beta-lactamase inhibitor designed to restore the efficacy of beta-lactam antibiotics by inhibiting enzymes responsible for antibiotic resistance. Nacubactam has shown broad-spectrum activity and effectiveness against complicated urinary tract and severe respiratory infections caused by resistant strains such as carbapenem-resistant Enterobacteriaceae, and has completed several phase 1 clinical trials demonstrating good tolerability and favorable pharmacokinetics. Fedora Pharmaceuticals is also developing additional early-stage antibiotic candidates and is open to partnerships and licensing agreements to support its pipeline. | Chief Tech/Sci/R&D Officer | 31/12/2013 |
Adaptive Therapeutics, Inc.
 Adaptive Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Chief Tech/Sci/R&D Officer | 30/11/2004 |
MicroGenomics, Inc.
 MicroGenomics, Inc. Miscellaneous Commercial ServicesCommercial Services Develops technology to uncover molecular and genetic diversity in microorganisms that can not be cultured in the laboratory | President | 30/04/2003 |
Xenogen Corp.
 Xenogen Corp. Medical SpecialtiesHealth Technology Provides real time in-vivo imaging services | Corporate Officer/Principal | 28/02/2002 |
Training of Thomas R. Parr
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
32
1st degree connections
13
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 13 |
|---|---|
Essential Therapeutics, Inc.
 Essential Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical goods for viral and fungal infections | Health Technology |
IntraBiotics Pharmaceuticals, Inc.
 IntraBiotics Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops antibacterial and antifungal drugs | Health Technology |
Xenogen Corp.
Xenogen Corp. Medical SpecialtiesHealth Technology Provides real time in-vivo imaging services | Health Technology |
Targanta Therapeutics Corp.
 Targanta Therapeutics Corp. BiotechnologyHealth Technology Discovers and develops novel antibacterial pro drugs | Health Technology |
Fedora Pharmaceuticals, Inc.
Fedora Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Fedora Pharmaceuticals, Inc. is an American private biopharmaceutical company focused on discovering and developing novel antimicrobial agents to address antimicrobial resistance. The company is located in the US. The company targets multi-drug resistant pathogens, including WHO-identified ESKAPE pathogens, and its lead product, nacubactam, is a phase 3-ready beta-lactamase inhibitor designed to restore the efficacy of beta-lactam antibiotics by inhibiting enzymes responsible for antibiotic resistance. Nacubactam has shown broad-spectrum activity and effectiveness against complicated urinary tract and severe respiratory infections caused by resistant strains such as carbapenem-resistant Enterobacteriaceae, and has completed several phase 1 clinical trials demonstrating good tolerability and favorable pharmacokinetics. Fedora Pharmaceuticals is also developing additional early-stage antibiotic candidates and is open to partnerships and licensing agreements to support its pipeline. | Commercial Services |
MicroGenomics, Inc.
MicroGenomics, Inc. Miscellaneous Commercial ServicesCommercial Services Develops technology to uncover molecular and genetic diversity in microorganisms that can not be cultured in the laboratory | Commercial Services |
University of Ottawa
 University of Ottawa Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Minnesota
 University of Minnesota Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Calgary
 University of Calgary Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Targanta Therapeutics, Inc.
 Targanta Therapeutics, Inc. BiotechnologyHealth Technology Develops antibiotic drugs and other related products | Health Technology |
Adaptive Therapeutics, Inc.
Adaptive Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Health Technology |
Lilly Research Laboratories
 Lilly Research Laboratories Miscellaneous Commercial ServicesCommercial Services Engages in research and develops medicines | Commercial Services |
Spero Therapeutics, Inc.
 Spero Therapeutics, Inc. BiotechnologyHealth Technology Develops therapies for the treatment of bacterial infections | Health Technology |
- Stock Market
- Insiders
- Thomas R. Parr
